Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. develops engineered T cell therapies for autoimmune diseases as a late-stage clinical biotechnology company. Its CABA platform includes the CARTA strategy, and its lead investigational therapy, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy evaluated through the RESET clinical development program across rheumatology, neurology and dermatology.
Recurring company updates cover rese-cel clinical and translational data, trial-program presentations, manufacturing scale-up, and supply arrangements using automated cell-therapy production platforms. News also includes financial results, business updates, conference participation, shareholder voting matters, capital-structure disclosures, and regulatory disclosures tied to Cabaletta Bio’s autoimmune cell-therapy pipeline.
Cabaletta Bio, Inc. (CABA) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company is actively enrolling patients in its Phase 1 trial for DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, expecting to report acute safety data in the first half of 2021. Q3 R&D expenses rose to $5.7 million from $3.2 million in Q3 2019, and G&A expenses increased to $2.8 million from $1.8 million. As of September 30, 2020, cash and equivalents stood at $118.1 million, down from $136.2 million at year-end 2019, enough to fund operations through Q3 2022.
Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B cell-mediated autoimmune diseases, announced that CEO Steven Nichtberger will speak at three investor conferences in October 2020. The presentations include:
- Stifel 2020 Immunology and Inflammation Virtual Summit on October 1 at 3:00 p.m. ET.
- Jefferies Virtual Cell Therapy Summit on October 5 at 8:30 a.m. ET.
- Chardan 4th Annual Genetic Medicines Conference on October 6 at 11:30 a.m. ET.
Webcasts will be available on the company’s website.
Cabaletta Bio, a clinical-stage biotechnology company, announced that Dr. Steven Nichtberger will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast of the event will be available on their website, with a replay accessible for 90 days. The company is focused on engineered T cell therapies for B cell-mediated autoimmune diseases, leveraging their Cabaletta Approach to selectively eliminate specific B cells while preserving normal ones. Their lead candidate, DSG3-CAART, targets mucosal pemphigus vulgaris.
Cabaletta Bio, Inc. (CABA) announced promising in vivo preclinical data for its Chimeric AutoAntibody Receptor T cells targeting MuSK-associated myasthenia gravis. Presenting at AAN 2020, the data showed the T cells effectively recognized and eliminated B cells expressing anti-MuSK antibodies, with no harm to normal B cells. The study supports plans for Investigational New Drug (IND)-enabling studies in 2020, addressing a significant unmet need in MuSK MG treatment.
Cabaletta Bio, Inc. (CABA) announced its Q1 2020 financial results, highlighting a significant milestone with the FDA granting Fast Track Designation for its lead candidate, DSG3-CAART, aimed at treating mucosal pemphigus vulgaris (mPV). The Phase 1 DesCAARTes™ trial is ready to launch pending COVID-19 restrictions. R&D expenses were $4.6 million, while G&A expenses totaled $3.3 million. Cash reserves stood at $131 million, projected to support operations through Q3 2022.